Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues

No abstract is available for this paper.

• Publication year

  2006

• Venue

  J. Comput. Aided Mol. Des.

• Publication date

  2006-08-08

• Fields of study

  Biology, Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1007/S10822-006-9050-6PMID 16897578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Emerging Roles of Non-Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Therapy

  2012cited by this paper
• Efavirenz

  2012cited by this paper
• Docking-based CoMFA and CoMSIA studies of non-nucleoside reverse transcriptase inhibitors of the pyridinone derivative type

  2004cited by this paper
• Inhibitory mode of indole-2-carboxamide derivatives against HLGPa: molecular docking and 3D-QSAR analyses.

  2004cited by this paper
• Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.

  2002cited by this paper
• Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215

  2002cited by this paper
• Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.

  2002cited by this paper
• New developments in anti-HIV chemotherapy

  2001cited by this paper
• New developments in anti-HIV chemotherapy

  2001cited by this paper
• 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.

  2001cited by this paper
• Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection

  2001cited by this paper
• Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.

  2001cited by this paper
• Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz.

  2001cited by this paper
• New drugs for the treatment of HIV infection

  2001cited by this paper
• Antiretroviral therapy: state of the HAART.

  2000cited by this paper
• Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis.

  2000cited by this paper
• Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.

  2000cited by this paper
• Nevirapine

  2000cited by this paper
• Molecular Clusters of pi-Systems: Theoretical Studies of Structures, Spectra, and Origin of Interaction Energies.

  2000cited by this paper
• Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.

  2000cited by this paper
• Structure-Based Design of Non-Nucleoside Reverse Transcriptase Inhibitors of Drug-Resistant Human Immunodeficiency Virus

  1999cited by this paper
• Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries

  1999cited by this paper
• Non-Nucleoside Reverse Transcriptase Inhibitors: The NNRTI Boom

  1999cited by this paper
• Structural biology of HIV.

  1999cited by this paper
• Strategies for Antiviral Drug Discovery

  1998cited by this paper
• HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology.

  1998cited by this paper
• L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

  1995cited by this paper
• Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution

  1995cited by this paper
• Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

  1995cited by this paper
• LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions.

  1995cited by this paper
• Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

  1995cited by this paper
• Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.

  1995cited by this paper
• A non-radioisotopic reverse transcriptase assay using biotin-11-deoxyuridinetriphosphate on primer-immobilized microtiter plates.

  1992cited by this paper
• Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

  1992cited by this paper
• Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

  1988cited by this paper
• Strategies for antiviral therapy in AIDS

  1987cited by this paper
• ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES

  1980cited by this paper
• Restart procedures for the conjugate gradient method

  1977cited by this paper

• Comparison of the Biological Characteristics and Molecular Mechanisms of Fludioxonil-Resistant Isolates of Botrytis cinerea from Tomato in Liaoning Province of China.

  2022cites this paper
• An overview of antiretroviral agents for treating HIV infection in paediatric population.

  2020cites this paper
• Drug discovery and computational strategies in the multitarget drugs era

  2018cites this paper
• HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).

  2017cites this paper
• M233I Mutation in the β-Tubulin of Botrytis cinerea Confers Resistance to Zoxamide

  2015cites this paper
• Resistance Mechanisms and Molecular Docking Studies of Four Novel QoI Fungicides in Peronophythora litchii

  2015cites this paper
• Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.

  2015cites this paper
• Synthesis of triazolo-fused benzoxazepines and benzoxazepinones via Passerini reactions followed by 1,3-dipolar cycloadditions

  2014cites this paper
• HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design

  2013cites this paper
• Residue-Ligand Interaction Energy (ReLIE) on a Receptor-Dependent 3D-QSAR Analysis of S- and NH-DABOs as Non-Nucleoside Reverse Transcriptase Inhibitors

  2012cites this paper
• Modeling anti-HIV compounds: the role of analogue-based approaches.

  2012cites this paper
• Key interactions of the mutant HIV-1 reverse transcriptase/efavirenz: an evidence obtained from ONIOM method

  2011cites this paper
• Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.

  2010cites this paper
• 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.

  2008cites this paper
• 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.

  2008cites this paper
• Synergies of virtual screening approaches.

  2008cites this paper